A recent study finds that there are large cost savings and many economic benefits associated with robotic-assisted laparoscopic prostatectomy.

A study titled “A Multidimensional Analysis of Prostate Surgery Costs in the United States: Robotic-Assisted versus Retropubic Radical Prostatectomy,” was recently published in Value in Health.

In the United States, prostate cancer is the most commonly diagnosed cancer among men and accounts for 27 percent of all cancer diagnoses. With the estimated direct costs of cancer diagnoses totaling over $125 billion, and more than 80 percent of prostate cancer surgeries done by robotic-assisted Laparoscopic Prostatectomy (RALP), the financial impact of prostatectomies on the healthcare economy is enormous.

In this study, researchers examined the financial impact of RALP versus Retropubic Radical Prostatectomy (RRP) for each radical prostatectomy by performing a systematic peer-reviewed literature search for clinical outcomes and by creating cost models for three different ways to assess the costs: hospital costs, payers’ expenditure and society’s expenses.

The results of the study revealed cost savings for hospitals, payers and society, when RALP surgeries are performed with da Vinci® Surgical Systems compared to RRP surgeries. Statistical analyses showed a clear cost savings with RALP for payers (99%) and society (83%) and for the individual hospital 38 to 79 percent of the time.3 While previous research has been limited to a single cost model, often direct hospital and robotic system costs, this study included multiple ways to assess the costs, reporting cost savings of $1,451 per patient for the payer and $1,202 per patient in societal savings.

“It is clear that the adoption of robotic-assisted Laparoscopic Prostatectomy eases the financial burden of prostate cancer on our healthcare system,” said Dr. Ashutosh Tewari, Professor and System Chair of Urology at Mount Sinai Health System. “As the healthcare providers strive to improve both patient outcomes and achieve greater value, this data shows that technologies like the da Vinci Surgical System can simultaneously deliver cost-effective treatment and care that can make surgery easier on patients.”

The study also calculated the costs of the robotic system in two different ways – as hospital overhead including hospital costs, inpatient bed, and inpatient days (resulting in $1,094 in hospital savings) and using the annual volume of robotic procedures ($341 in extra costs). This demonstrates that potentially higher robotic surgical expenditures are counteracted by cost savings due to better clinical outcomes, including reduced complications , improved functional outcomes (e.g. continence and sexual function), and a faster recovery.

“This study further demonstrates that hospital administrators need to look beyond visible operating room costs when analyzing the robotic-assisted surgery value proposition,” said Myriam Curet, M.D., Senior Vice President, Chief Medical Officer at Intuitive Surgical, Inc. “The ability of robotic-assisted surgery to reduce complications and shorten hospital stays, undoubtedly leads to greater value for patients and healthcare providers.”

To view the full article please cut and paste this url into your browser:

http://finance.yahoo.com/news/study-results-cost-savings-associated-123000348.html;_ylc=X1MDMTE5Nzc4NDE4NQRfZXgDMQRfeXJpZAMyZ2FjczMxYmc3Y2IyBGcDZFhWcFpEeHVjejVqWTJZM01qa3pPUzB3TTJJeExUTm1OVEF0T1RFd1lpMHdNbUl5T0RObU56VTRZalE4Wm1sbGJHUSthWE55Wnc9PQRsYW5nA2VuLVVTBG9yaWdfbGFuZwNlbgRvcmlnX3JlZ2lvbgNVUwRwb3MDMwRyZWdpb24DVVMEc3ltYm9sA0lTUkc-?.tsrc=applewf

Compounds with the potential of fighting prostate cancer have been identified by scientists

Eleven compounds that have the potential to significantly improve the treatment and diagnosis of prostate cancer have recently been identified by a group of scientists, who say the compounds could be used in the future to develop more effective and targeted drugs. Currently prostate cancer is similar to most other types of cancer in that it is fought using drugs that damage healthy cells as well as cancerous ones.

Researchers in four institutions across Russia looked at a cancer marker called the prostate specific membrane antigen (PSMA), to determine whether specific types of molecules can be more selective in the type of cells they target. Prostate cancer tissues have 10 times the level of PSMA proteins. These PSMAs can be a highly effective way of spotting secondary tumors that could be present after the removal of the initial tumor.

Once the PSMA was identified, the scientists evaluated three different groups of molecules capable of binding to it. After a detailed analysis, the team identified ligands as having the best potential to offer a targeted approach to prostate cancer, and the team was able to build on previous work done in this area. The scientists highlighted a set of eleven promising cancer-fighting compounds based on a substance called urea. Urea is a part of urine and has long been of interest to cancer specialists because of the way it can be modified to block DNA replication and thus the division of cancer cells.

The team reported that they have discovered eleven substances that have demonstrated the characteristics necessary. These substances are now being tested in clinical trials and according to the scientists, the results so far are encouraging.

According to the US National Cancer Institute, prostate cancer is the second most common cancer in men after skin cancer, and despite the fact that most men don’t die from the disease, it’s still the second most common cause of cancer-related death in the US after lung cancer.

The study referred to in this article has been published in the Journal of Drug Targeting.

PSA Testing Differs Among Primary Care Doctors, Urologists

When it comes to prostate-specific antigen (PSA) testing, a new study reports that urologists are far more likely than primary care doctors to do perform these prostate cancer screenings.

The test is simple. blood sample is taken and sent to a laboratory to check for levels of a protein produced by cells of the prostate gland.

After the U.S. Preventative Services Task force recommended against routinely screening all men in 2011, PSA testing declined overall. New research shows that the decline in number of men tested was sharper among primary care doctors than urologists.

PSA testing decreased from 36 percent to 16 percent at primary care physician visits between 2010 and 2012. Researchers found that the decline in PSA testing was much smaller in urologist visits, dropping from 39 percent to 34 percent.

This discrepancy may reflect different perceptions of the benefits of the test among doctors, according to a study published online in JAMA Internal Medicine.

This much larger decline in PSA testing among primary care doctors could also stem from conflicting prostate cancer screening guidelines and differences in patients’ demographics or expectations, the study authors suggested.

The research team used the National Ambulatory Medical Care Survey to examine PSA testing one year before and one year after the task force recommendations were issued.

The study involved nearly 1,200 preventive office visits made by men aged 50 to 74 who were not diagnosed with cancer or any other prostate condition. Primary care doctors were seen in 1,100 of these visits. The others were examined by a urologist, a doctor who specializes in the urinary tract.

Prostate Cancer Update: 2016

Prostate cancer is the most common non-cutaneous malignancy diagnosed in men. Last year in the U.S. an estimated 240,000 men were diagnosed with the disease, and 29,000 died because of prostate cancer. Approximately one in six men will be diagnosed with prostate cancer in their lifetime.

Over the last five to 10 years we have seen dramatic changes in the way prostate cancers are detected and treated. Traditionally, prostate cancer was detected using PSA testing and digital rectal exam with the primary treatments being surgery and/or radiation. For metastatic disease, patients were treated with hormonal therapy and cytotoxic chemotherapy. In this article we will discuss what’s new in prostate cancer screening, diagnosis, and treatment of localized and metastatic disease.

Screening

The PSA (prostate specific antigen) blood test is the most widely used screening test for prostate cancer since it first came into use in 1994. Men who are screened for prostate cancer using PSA are more likely to find their cancers earlier and have a higher chance of cancer cure. It is, however, not a perfect test, and many patients and physicians question its role in prostate cancer screening.

First, a PSA test can give both falsepositive and false-negative readings. Men with normal PSA readings may have prostate cancer, a false negative. More commonly, men with high PSA readings do not have cancer, a false positive. Men with high readings but without cancer go through unnecessary prostate biopsies and follow-up testing.

Second, prostate cancer in many men is indolent. PSA screening detects nonlethal as well as lethal cancers. One of the key challenges is differentiating those cancers which can be followed via active surveillance and those potentially aggressive cancers that will lead to significant morbidity and mortality. Most experts agree that not every prostate cancer needs to be treated. A significant trend clinically has been the acceptance by patients that not all cancers need immediate, aggressive treatment.

Controversy regarding PSA testing increased substantially after the U.S. Preventative Services Task Force came out with its position statement in 2010, giving the PSA blood test a “D” rating as a screening tool. Although many urologists and oncologists were critical of the rating, many practitioners at the primary care level drastically changed their discussion with patients and practice patterns regarding PSA testing. Patients also became more critical of the test after heavy publicity of the USPSTF rating.

In 2013, the American Urologic Association established its own guidelines. The AUA does not support the USPSTF position on PSA screening. The AUA recommends the omission of PSA screening for men with a life expectancy less than 10 years or those under 40. For all other men the AUA advocates shared decisionmaking for men and their physician regarding PSA testing; especially those men between ages 55-70 or those with a strong family history of disease.
Shared decision-making relies heavily on the guidance of a medical practitioner looking out for the best interest of the patient. We would encourage you to review the AUA guidelines at: www.auanet.org/education/guidelines/prostate-cancer-detection.cfm
As urologists we strongly advocate for prostate cancer screening. In 2015 the current standard is the PSA test; in the future we hope a more cancer-specific test will emerge.

Diagnosis

The PSA is a basic screening test. It is often a starting point with patients as we discuss whether to perform a prostate biopsy, and, if a cancer is found, whether treatment or surveillance is most appropriate. Here we have also seen advances.

There are new genetic and biomarker studies which have added to our ability to find prostate cancers.
Examples include the PHI (Prostate Health Index) or a 4Kscore- measures 3 or 4 different types of PSA kallikreins in the blood, and the PCA3; a urine test that looks for a protein that is produced by prostate cancer cells. These tests are used to predict risk of high grade cancer prior to a patient having a biopsy. Advances in genetic testing allow us to better determine which cancers should be treated. Examples of this include the Oncotype DX and Prolaris-genetic tests run on a biopsy specimen to help determine if the biopsy sample represents low or higher risk disease.

Recent advances in MRI of the prostate have improved our ability to identify prostate cancers and, in some cases, differentiating indolent from aggressive tumors. Urologists traditionally use trans-rectal ultrasound as a guide during a prostate biopsy, but the ultrasound is a low-resolution image. We now have software that can fuse a fixed MRI image with real time ultrasonography. The radiologists reading the MRI will draw out specific areas requiring biopsy; the urologist can “fuse” that image with the ultrasound and insure that those specific areas are biopsied. This sequence creates a more targeted biopsy, detecting cancers we may have otherwise missed.

Treatment of Localized Disease

There is an increasing interest in active surveillance for low-grade prostate cancers. Active surveillance is a close monitoring process that typically involves frequent PSA testing and rectal exams, repeat prostate biopsies, and imaging studies such as MRI to try to detect progression of disease. While active surveillance is gaining traction, the gold standard for treatment of prostate cancer remains radical prostatectomy. Over the last decade daVinci robotic radical prostatectomy has emerged as the preferred surgical approach in the overwhelming majority of hospitals and centers of excellence. Robotic prostatectomy has shortened recovery times, decreased blood loss and, in experienced hands, improved outcomes.

Radiation, brachytherapy seed placement, cryotherapy (freezing), and a recently FDA approved treatment, highintensity focused ultrasound (HIFU), are also options for treatment of localized prostate cancer. Traditionally we treat or remove the entire prostate, even the benign ti ssue.

A different and developing strategy is focal therapy. Using some of the newer technology such as HIFU or cryotherapy we can ablate only the cancerous lesion while leaving the normal prostate intact. While focal therapy is not yet considered standard of care, improving imaging with MRI and other means of identifying the tumor location within the prostate will likely make focal therapy a more common and standard option in the near future.

Treatment of Advanced Disease

Prostate cancer is hormone sensitive and creating castrate levels of testosterone can help control the disease. Androgen deprivation therapy (ADT) uses either surgical castration, medical castration, and/or combined androgen blockade with the use of anti-androgens.

Despite initial tumor response to ADT, most cases will become resistant over time. Historically once the cancer became castrate resistant (CRPC) the only options were cytotoxic chemotherapy. Newer treatments have shown improved survival.

Abiraterone acetate (Zytiga) and Enzalutamide (Xtandi) are second-line inhibitors of androgen activity in the body either by reducing production (Ztytiga) or by androgen receptor blockage (Xtandi). Both are being used commonly by urologists and oncologists for treatment after failure of initial ADT. Both show very good response and extension of survival.

Sipuleucel-T (Provenge) was a first of its kind cancer vaccine. It involves the autologous infusion of patient’s own blood cells after they are exposed to the prostate cancer antigen in a lab. It has been shown to extend overall survival as well.

Radium 223 (Xofigo) is a radioactive agent used to target bone metastases. It is especially useful for men with late stage, painful bony metastatic disease.

Conclusion

The landscape of prostate cancer diagnosis and treatment continues to evolve and improve. We believe this will help the lives of the many men diagnosed with prostate cancer. As urologists who are part of a larger practice, Metro Urology, that focuses on prostate cancer we see the benefit of adopting and employing these new technologies. We are excited about the future of prostate cancer care.

Todd Brandt, MD, has practiced with Metro Urology since 2000, focusing on prostate cancer and men’s health.

Basir Tareen, MD, is a fellowship-trained urologic oncologist. He has practiced with Metro Urology since 2011.

New Research Into The Prevention Of Prostate Cancer

Researchers continue to look for foods (or substances in them) that can help lower prostate cancer risk. Scientists have found some substances in tomatoes (lycopenes) and soybeans (isoflavones) that might help prevent prostate cancer. Studies are now looking at the possible effects of these compounds more closely. Scientists are also trying to develop related compounds that are even more potent and might be used as dietary supplements. So far, most research suggests that a balanced diet including these foods as well as other fruits and vegetables is of greater benefit than taking these substances as dietary supplements.

Some studies have suggested that certain vitamin and mineral supplements (such as vitamin E and selenium) might lower prostate cancer risk. But a large study of this issue, called the Selenium and Vitamin E Cancer Prevention Trial (SELECT), found that neither vitamin E nor selenium supplements lowered prostate cancer risk after daily use for about 5 years. In fact, men taking the vitamin E supplements were later found to have a slightly higher risk of prostate cancer.

Another vitamin that may be important is vitamin D. Some studies have found that men with high levels of vitamin D seem to have a lower risk of developing the more lethal forms of prostate cancer. Overall though, studies have not found that vitamin D protects against prostate cancer.
Many people assume that vitamins and other natural substances cause no harm, but recent research has shown that high doses may be harmful, including those in supplements marketed specifically for prostate cancer. For example, one study found that men who take more than 7 multivitamin tablets per week may have an increased risk of developing advanced prostate cancer. Another study showed a higher risk of prostate cancer in men who had high blood levels of omega-3 fatty acids. Fish oil capsules, which some people take to help with their heart, contain large amounts of omega-3 fatty acids.

Some research has suggested that men who take aspirin daily for a long time might have a lower risk of getting and dying from prostate cancer, but more research is needed to confirm this.
Scientists have also tested certain hormonal medicines called 5-alpha reductase inhibitors as a way of reducing prostate cancer risk.

Scientists Determine That There May Be Five Types of Prostate Cancer

English scientists say that there are five distinct types of prostate cancer, and they’ve found a way to distinguish between them. This research could possibly lead to better treatments of the disease because doctors would be able to know which tumors are more likely to grow and spread.
The team, from the Cancer Research UK Cambridge Institute and Addenbrooke’s Hospital, studied samples of healthy and cancerous prostate tissue from more than 250 men. To group the tumors into five distinct types, they looked for abnormal chromosomes and measured the activity of 100 different genes linked to prostate cancer.

In the journal EBioMedicine, they say this form of analysis was more accurate at picking up the most aggressive types of prostate cancer than tests currently used by doctors, including the prostate specific antigen (PSA) test. But further and larger trials are needed to confirm the findings, they say.

Dr. Alastair Lamb, one of the researchers, calls the results exciting. “These findings could help doctors decide on the best course of treatment for each individual patient, based on the characteristics of their tumor,” he says in a statement.”By carrying out more research into how the different diseases behave, we might be able to develop more effective ways to treat prostate cancer patients in the future, saving more lives.”
Prostate cancer is the second most common cancer in U.S. men, behind skin cancer, according to the American Cancer Society. In 2015, the society estimates, about 220,800 new cases will be diagnosed, and about 27,540 men will die. About 1 man in 7 is diagnosed with prostate cancer during his lifetime, according to the society.

Expert: Research Could Be a Game-Changer

“The challenge in treating prostate cancer is that it can either behave like a pussycat — growing slowly and unlikely to cause problems in a man’s lifetime — or a tiger, spreading aggressively and requiring urgent treatment,” says Professor Malcolm Mason, Cancer Research UK’s prostate cancer expert. “But at the moment we have no reliable way to distinguish them. This means that some men may get treatment they don’t need, causing unnecessary side effects, while others might benefit from more intensive treatment.
“This research could be game-changing if the results hold up in larger clinical trials, and could give us better information to guide each man’s treatment — even helping us to choose between treatments for men with aggressive cancers. Ultimately this could mean more effective treatment for the men who need it, helping to save more lives and improve the quality of life for many thousands of men with prostate cancer.”

Chemotherapy in combination with hormone therapy in advanced prostate cancer

A new study has concluded that chemotherapy at the start of hormone therapy can extend the lives of men with prostate cancer that has spread beyond the gland.

Over nearly 29 months of follow-up, men with advanced prostate cancer who received the combination therapy lived almost 14 months longer than men who received only hormone therapy (58 months versus 44 months), researchers said.

Men who have hormone-sensitive metastatic prostate cancer should consider speaking with their doctors about having this combination treatment to significantly prolong their survival. For 50 years, hormone therapy has been the standard care for these patients, but adding chemotherapy to hormone therapy may be worth doing because even though it’s not a cure, it could very well improve survival and quality of life.

The study was funded by the U.S. National Cancer Institute, and the report was published Aug. 5 online in the New England Journal of Medicine.

For the study, 790 men with prostate cancer, average age 63 were randomly assigned to have either chemotherapy plus hormone therapy or hormone therapy alone.

In addition to the survival benefit, men who received the combination of chemotherapy and hormone therapy saw their cancer remain dormant for more than 20 months before it began to progress, compared with close to 12 months among those who only received hormone therapy, researchers found.

The side effects of the chemotherapy were mild, in general. Fatigue, low white blood cell count and infection were the most common side effects, the study said.

One of the criteria for the treatment is that patients should be able to handle the chemotherapy. If they have other conditions such as liver or kidney disease, they should not be getting chemotherapy. In the study, the greatest benefit was seen in men who had four or more tumors outside the prostate.

Other studies have confirmed these findings.

Common Myths About Prostate Cancer

Myth Number One: Everyone that gets prostate cancer will die of the disease.

Fact: Checking for prostate cancer is incredibly important, but patients with prostate cancer are likely live to an old age and/or die of some other cause. Detecting prostate cancer early and working with expert doctors like Dr. Gaertner and Dr. Knoedler on a treatment plan is crucial.

Myth Number Two: If you have high PSA score that you definitely have prostate cancer.

Fact: Some high PSA scores can be due to an inflammation in the prostate or an enlarged prostate. The PSA score is a guideline to help Dr. Knoedler or Dr. Gaertner decide if you need more tests to check for prostate cancer. The doctors are interested in your PSA score over time. If it continues to increase it could be a sign of a problem. If it decreases after cancer treatment that is great.

Patients at Metro Urology now have access to UroNav, which is an MRI assisted, ultrasound-guided biopsy technique which provides a new level of accuracy to the detection of prostate cancer. Because it can detect prostate cancers in hard to find areas of the prostate, UroNav can reduce the need for multiple biopsies and find cancers in men with previous negative biopsies but high/rising PSA scores.

UroNav is a new high tech approach to the diagnosis of prostate cancer and Metro Urology is the only private urology practice in the Twin Cities to have this technology. UroNav testing has already found aggressive prostate cancers in men with previous negative biopsies.

Myth Three: Prostate cancer surgery will ultimately end your sex life and cause urine leakage.

Fact; Sex Life: Using the highest tech equipment to perform robotic surgery with the da Vinci system, Dr. Knoedler and Dr. Gaertner work to spare the nerves that help trigger erections. Because of their combined talents they have a great success rate with patients that are able to have an erection strong enough for sex again. Depending on the patient, recovery can take from 4 to 24 months, maybe longer and in general younger men usually recover sooner.

Fact; Urine Leakage: While urine leakage is common immediately after surgery it is almost always temporary. Dr. Gaertner and Dr. Knoedler have an excellent success rate in this area and within a year, approximately 95% of men have as much bladder control as they did before surgery.

Myth Four: The only men at risk of prostate cancer are elderly.

Fact: Although prostate cancer is fairly rare for men under 40 some men should be tested earlier. Age is not the only risk factor for the disease. Others include:

Family history. For patients whose father or brother had prostate cancer, their own risk doubles or triples. The more relatives a patient has with the disease, the greater their chances of getting it.
Race. African-American men have a higher risk of prostate cancer than men of other races, the reason is still unknown.

Talk to Dr. Gaertner and Dr. Knoedler about when you should start PSA testing.

Myth Five: Patients must have all prostate cancers treated.

Fact: In some cases patients and their doctors may decide not to treat prostate cancer. Reasons include:

If the cancer is at an early stage and is growing very slowly.
If the patient is elderly and has other illnesses. In cases like these the treatment for prostate cancer may not prolong life and may actually complicate care for other health problems.

In such cases Dr. Gaertner and Dr. Knoedler may suggest “active surveillance.” This means that they will regularly check the patient to make sure the cancer does not worsen. If the situation changes, the doctors may decide to start treatment.

15 Cancer Symptoms Men Tend to Ignore

One of the best ways to fight cancer is to catch it in the early stages, when it’s more treatable. The problem is that the warning signs for many kinds of cancer can seem pretty mild.

Take a look at these 15 signs and symptoms. Some are linked more strongly to cancer than others, but all are worth knowing about — and even talking over with your doctor.

1. Problems When You Pee

Many men have some problems peeing as they get older, like:

A need to pee more often, especially at night
Dribbling, leaking, or an urgent need to go
Trouble starting to pee, or a weak stream

An enlarged prostate gland usually causes these symptoms, but so can prostate cancer. See your doctor to check on the cause of the problem. He’ll give you an exam to look for an enlarged prostate, and he may talk to you about a blood test (called a PSA test) for prostate cancer.

2. Changes in Your Testicles

If you notice a lump, heaviness, or any other change in your testicle, never delay having it looked at. Unlike prostate cancer, which grows slowly, testicular cancer can take off overnight. Your doctor will look for any problems with a physical exam, blood tests, and an ultrasound of your scrotum.

3. Blood in Your Pee or Stool

These can be among the first signs of cancer of the bladder, kidneys, or colon. It’s a good idea to see your doctor for any bleeding that’s not normal, even if you don’t have other symptoms. Although you’re more likely to have a problem that’s not cancer, like hemorrhoids or a urinary infection, it’s important to find and treat the cause.

4. Skin Changes

When you notice a change in the size, shape, or color of a mole or other spot on your skin, see your doctor as soon as you can. Spots that are new or look different are top signs of skin cancer. You’ll need an exam and perhaps a biopsy, which means doctors remove a small piece of tissue for testing. With skin cancer, you don’t want to wait.

5. Changes in Lymph Nodes

Swollen lymph nodes, small bean-shaped glands found in your neck, armpits, and other places, often signal that something’s going on in your body. Usually, they mean your immune system is fighting a sore throat or cold, but certain cancers also can make them change. Have your doctor check any swelling that doesn’t get better in 2 to 4 weeks.

6. Trouble Swallowing

Some people have trouble swallowing from time to time. But if your problems don’t go away and you’re also losing weight or vomiting, your doctor may want to check you for throat or stomach cancer. He’ll start with a throat exam and barium X-ray. During a barium test, you drink a special liquid that makes your throat stand out on the X-ray.

7. Heartburn

You can take care of most cases of heartburn with changes to your diet, drinking habits, and stress levels. If that doesn’t help, ask your doctor to look into your symptoms. Heartburn that doesn’t go away or gets worse could mean stomach or throat cancer.

8. Mouth Changes

If you smoke or chew tobacco, you have a higher risk of mouth cancer. Keep an eye out for white or red patches inside your mouth or on your lips. Talk to your doctor or dentist about tests and treatments.

9. Weight Loss Without Trying

Pants fitting a little looser? If you haven’t changed your diet or exercise habits, it could mean that stress or a thyroid problem is taking a toll. But losing 10 pounds or more without trying isn’t normal. Although most unintended weight loss is not cancer, it’s one of the signs of cancer of the pancreas, stomach, or lungs. Your doctor can find out more with blood tests and tools that make detailed pictures of the inside of your body, like a CT or PET scan.

10. Fever

A fever is usually not a bad thing — it means your body is fighting an infection. But one that won’t go away and doesn’t have an explanation could signal leukemia or another blood cancer. Your doctor should take your medical history and give you a physical exam to check on the cause.

11. Breast Changes

Men tend to ignore breast lumps because breast cancer isn’t on their radar. But 1% of all breast cancers occur in men, although they’re usually diagnosed much later. Don’t take any chances. If you find a lump, tell your doctor and have it checked.

12. Fatigue

Many types of cancer cause a bone-deep tiredness that never gets better, no matter how much rest you get. It’s different from the exhaustion you feel after a hectic week or a lot of activity. If fatigue is affecting your daily life, talk to your doctor who can help you find the cause and let you know if there are ways to treat it.

13. Cough

In nonsmokers, a nagging cough is almost never cancer. Most go away after 3 to 4 weeks. If yours doesn’t, and you’re short of breath or cough up blood, don’t delay a visit to your doctor, especially if you smoke. A cough is the most common sign of lung cancer. Your doctor can test mucus from your lungs to see if you have an infection. He may also give you a chest X-ray to check for another problem.

14. Pain

Cancer doesn’t cause most aches and pains, but if you’re hurting for more than a month, don’t just grin and bear it. Ongoing pain can be a signal of many types of cancer, especially those that have spread.

15. Belly Pain and Depression

It’s rare, but depression along with stomach pain can be a sign of cancer of the pancreas. Should you worry? Not unless this cancer runs in your family. Then you need to see your doctor.

Kegel Exercise for Men Post-Prostate Surgery

When you have prostate cancer surgery or radiation therapy the muscles that help you control your urine flow may be weakened. When this happens you may have incontinence. Incontinence is when you leak or pass urine when you do not want to. This is a very common side effect or unwanted change of prostate cancer treatment. The good news is that there is a simple exercise, called a Kegel (Keygul) exercise which you can do to help strengthen your muscles. This exercise will help you have more control over your urine flow after your prostate cancer treatment. In this article you will learn:

What a Kegel exercise is
Why you should do Kegel exercises
How to find your pelvic floor muscles
How often you should do your Kegel exercises

It is important for you to think about and plan how you will take care of yourself before and after your prostate cancer treatment so that you can keep doing as many of your normal activities as possible.

What Are Pelvic Floor Muscles?

Your pelvic floor muscles are a network of muscles that support your bladder and help you control your urine flow. There are three pelvic muscles:

The bladder. Your bladder is a muscle shaped like a balloon and holds your urine.
The sphincter muscles. These muscles help you open and close your urethra, the tube that drains urine from your bladder. And,
The pelvic floor muscle [also known as the pubococcygeus (pu-bo-kak-sije- us) or PC muscle] supports your bladder and rectum and helps control your urine flow.

What are Kegel Exercises?

Kegel exercises are easy exercises you can do before and after your prostate cancer treatment to help strengthen your pelvic floor muscles. These muscles help control your urine flow. Kegel exercises are one of the most effective ways of controlling incontinence without medication or surgery.

Why Should I Do Kegel Exercises?

The prostate is a gland, about the size of a walnut, located under the bladder surrounding the upper part of the urethra. The urethra is a tube that carries urine through the penis to the outside of the body. There are many muscles that surround the prostate gland. These muscles may be weakened during your prostate cancer treatment. This may cause you to have urine leakage also known as incontinence. Building up the strength in your pelvic floor muscles can help you gain better control of your bladder and urine flow. Remember, that just as it takes time to build your biceps and strengthen any other muscle in your body, it takes time to strengthen muscles in your pelvic floor.

How Do I Find My Pelvic Floor Muscles?

In order to help strengthen you pelvic floor muscles, it is important that you take time to make sure you are exercising the right muscles. It may take you several tries to find your pelvic muscles. So, take your time.

There are several ways that you can find your pelvic floor muscles. One way is to:

Try to stop and start your urine stream while you stand at your toilet to urinate (pee). Try to do this two or three times.

Another way to find your pelvic floor muscles is to:

Imagine that someone walks in to your bathroom while you are urinating (peeing) and you need to stop your urine flow.
Try to stop your urine flow.

The muscles you use to stop your urine flow are your pelvic floor muscles. These are the muscles you want to strengthen before and after your prostate cancer treatment.

How Do I Do A Kegel Exercise?

Now that you have located your pelvic floor muscles, you can exercise them even when you do not have to urinate by following these simple steps:

Tighten and hold your pelvic floor muscles for five seconds (count 1 one thousand, 2 one thousand, 3 one thousand, 4 one thousand, 5 one thousand).
Relax your pelvic muscles. You have just done one Kegel exercise. You should plan to do 10 to 20 Kegel exercises three to four times each day.

Another way to tighten your pelvic floor muscles is to:

Squeeze the muscles in your anus (like you are holding a bowel movement).
Relax your pelvic floor muscles after each attempt.
Repeat this exercise 10 to 20 times.

When you do your Kegel exercises, remember

Do not hold your breath.
Do not push down. Squeeze your muscles together tightly and imagine that you are trying to lift this muscle up.
Do not tighten the muscles in your stomach, buttocks, or thighs.
Relax your pelvic floor muscles between each squeeze.

How Often Should I Do My Kegel Exercises?

When you first start doing your Kegel exercises, you may not be able to repeat the exercise 10 to 20 times. This is ok. It is much better for you to do fewer Kegel exercises that make your pelvic floor muscles stronger, than to do more exercises that do not work the muscle in the right way. As you get better at doing your Kegel exercises, slowly increase the number of times you repeat the exercise until you reach 20. Your goal should be to do 20 Kegel exercises three to four times each day.

The great thing about Kegel exercises is that you can do them anytime you want to do them. No one can tell that you are doing these exercises. You do not need any special equipment to do Kegel exercises. You can do your Kegel exercises before you get up in the morning, at lunchtime, at suppertime, and at bedtime. You can do them while you are watching TV or reading. Some men put notes on their refrigerator or on their bathroom mirror to remind them to do their Kegel exercises. The more you do them, the stronger your pelvic floor muscles will become.

When Should I Do The Kegel Exercises?

It can take six weeks or longer to strengthen your pelvic floor muscles so it is best to start doing your Kegel exercises before you have prostate cancer treatment. This will help you become better at doing the Kegel exercises and strengthen your pelvic floor muscles before your treatment starts. Remember, your pelvic floor muscles are like any other muscle in your body. It takes regular exercise and time to strengthen them.

Can I do Kegel Exercises If I Have A Catheter?

A catheter is a thin rubber tube placed in your body to drain urine from your bladder out through your penis. Do not do any Kegel exercises if you have a catheter in your penis.

Start doing your Kegel exercises according to the instructions above as soon as the catheter is taken out of your penis. After your catheter is removed you may experience some urine leakage (incontinence) when you stand up, cough, sneeze, laugh, or lift something. You will probably need to use incontinence pads for a while. However, doing Kegel exercises may help you control your urine flow sooner. If you have urine leakage when you stand up, cough, sneeze, laugh, or lift something, try doing a Kegel exercise. This may keep you from leaking urine.

Will My Urine Leakage Stop if I Do The Kegel Exercises?

Most men gain control of their urine leakage (incontinence) within nine to 12 months after their surgery. Studies with men show that Kegel exercises help lessen urine leakage. However, each man’s healing time is different.

Do not become discouraged if you have urine leakage. If you do your Kegel exercises on a daily basis, you can expect to see some results. You may have a great improvement or you may help keep your urine leakage from getting worse. You will need to continue doing your Kegel exercises each day so that your pelvic floor muscles stay strong.

If you have any questions or concerns about urine leakage (incontinence), how to do a Kegel exercise, or if you would like to know about other things that may help with urine leakage, please talk to Dr. Gaertner or Dr. Knoedler.